A PYMNTS Company

Denmark/UK: Baxalta signs off on $32 billion deal

By  |  January 4, 2016
 

Baxalta Inc. has agreed to pay Danish biotechnology company Symphogen A/S up to $1.6 billion for the rights to co-develop six experimental cancer drugs, as it nears a multibillion-dollar takeover deal with Shire PLC.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    Deerfield, Ill.-based Baxalta is in advanced talks for Dublin-based Shire to take it over in a deal worth up to $ 32.6 billion, according to a person familiar with the matter, who said an agreement could be announced later this week.

    We’d love to be your preferred source for news.

    Please add us to your preferred sources list so our news, data and interviews show up in your feed. Thanks!

    Add as Preferred Source
    In the past week, the two companies have been discussing a cash-and-stock deal with a per-share value of up to $48, according to the person, who added that some details still needed to be ironed out and an agreement wasn’t certain.
    In the Symphogen transaction announced Monday, Baxalta said it would pay the closely held Danish company $175 million upfront for the exclusive rights to co-develop and commercialize the six early-stage drugs. It then would make milestone payments worth up to $1.4 billion should the drugs successfully complete clinical trials and win regulatory approval.
    The companies expect the most advanced of the drugs to enter human trials in 2017.

    Full content: The Wall Street Journal

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.